Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + trametinib
- Development stage
- Unknown
- Lead developer
- Shanghai Chest Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Anlotinib + trametinib is a combination therapy that targets multiple pathways in cancer treatment. Anlotinib is a novel, orally administered multi-targeting tyrosine kinase inhibitor (TKI) that targets several receptor tyrosine kinases (RTKs). Trametinib is a MEK inhibitor. The combination strategy involves co-inhibition of MEK/RTKs pathways, which has shown promising activity particularly in non-G12C KRAS-mutant non-small cell lung cancer (NSCLC). This combination has demonstrated significant efficacy in clinical trials with favorable objective response rates, progression-free survival, and disease control rates.
02
Targets
KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on anlotinib + trametinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + trametinib.